TY - JOUR
T1 - Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy
T2 - a multi-institutional study
AU - Shiota, Masaki
AU - Nakamura, Motonobu
AU - Yokomizo, Akira
AU - Tomoda, Toshihisa
AU - Sakamoto, Naotaka
AU - Seki, Narihito
AU - Hasegawa, Shuji
AU - Yunoki, Takakazu
AU - Harano, Masahiko
AU - Kuroiwa, Kentaro
AU - Eto, Masatoshi
N1 - Funding Information:
We would like to acknowledge the contributions from the following collaborators; Akito Yamaguchi in Harasanshin Hospital (Fukuoka), Takashi Dejima in Kyushu Central Hospital (Fukuoka), Satoshi Otsubo in Kitakyushu Municipal Medical Center (Kitakyushu), Akio Tsutsui in JCHO Kyushu Hospital (Kitakyushu), and Yoshifumi Hori in Miyazaki Prefectural Miyazaki Hospital (Miyazaki). We thank Cathel Kerr, B.Sc., Ph.D., from Edanz Group (http://www.edanzediting.com/ac ) for editing a draft of this manuscript.
Funding Information:
supported by JSPS KAKENHI Grant
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - This multi-institutional study aimed to investigate the efficacy and safety profiles of cabazitaxel after prior docetaxel chemotherapy in patients with castration-resistant prostate cancer (CRPC). This study included 63 Japanese patients with CRPC who were treated with cabazitaxel from 2014 to 2017. The oncological outcomes and adverse events (AEs) were documented, and prognostic factors for oncological outcomes and predictive factors for AEs were analysed. PSA decline was observed in 68.3% of patients, including 25.4% who achieved a ≥ 50% decline. The median progression-free survival, treatment failure-free survival, and overall survival were 4.3, 4.1, and 9.0 months, respectively. More cycles of prior docetaxel therapy was identified as common favourable prognostic factors for progression-free survival, treatment failure-free survival, and overall survival. Severe neutropenia, febrile neutropenia, and severe non-haematological AEs were observed in 73.0%, 33.3%, and 23.8% of patients, respectively. However, > 10 cycles of docetaxel was not associated with increased incidence of AEs. In conclusion, cabazitaxel chemotherapy was still active in Japanese CRPC patients treated with > 10 cycles of docetaxel chemotherapy, with an acceptable risk of AE burden. Treatment with cabazitaxel after > 10 cycles of docetaxel may be an appropriate option when it can be administered.
AB - This multi-institutional study aimed to investigate the efficacy and safety profiles of cabazitaxel after prior docetaxel chemotherapy in patients with castration-resistant prostate cancer (CRPC). This study included 63 Japanese patients with CRPC who were treated with cabazitaxel from 2014 to 2017. The oncological outcomes and adverse events (AEs) were documented, and prognostic factors for oncological outcomes and predictive factors for AEs were analysed. PSA decline was observed in 68.3% of patients, including 25.4% who achieved a ≥ 50% decline. The median progression-free survival, treatment failure-free survival, and overall survival were 4.3, 4.1, and 9.0 months, respectively. More cycles of prior docetaxel therapy was identified as common favourable prognostic factors for progression-free survival, treatment failure-free survival, and overall survival. Severe neutropenia, febrile neutropenia, and severe non-haematological AEs were observed in 73.0%, 33.3%, and 23.8% of patients, respectively. However, > 10 cycles of docetaxel was not associated with increased incidence of AEs. In conclusion, cabazitaxel chemotherapy was still active in Japanese CRPC patients treated with > 10 cycles of docetaxel chemotherapy, with an acceptable risk of AE burden. Treatment with cabazitaxel after > 10 cycles of docetaxel may be an appropriate option when it can be administered.
UR - http://www.scopus.com/inward/record.url?scp=85062213854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062213854&partnerID=8YFLogxK
U2 - 10.1007/s12032-019-1257-1
DO - 10.1007/s12032-019-1257-1
M3 - Article
C2 - 30815799
AN - SCOPUS:85062213854
SN - 1357-0560
VL - 36
JO - Medical Oncology
JF - Medical Oncology
IS - 4
M1 - 32
ER -
